Hernandez-Davies, Jenny E.
Dollinger, Emmanuel P.
Pone, Egest J.
Felgner, Jiin
Liang, Li
Strohmeier, Shirin
Jan, Sharon
Albin, Tyler J.
Jain, Aarti
Nakajima, Rie
Jasinskas, Algimantas
Krammer, Florian
Esser-Kahn, Aaron
Felgner, Philip L.
Nie, Qing
Davies, D. Huw
Funding for this research was provided by:
National Institute of General Medical Sciences (T32GM136624, T32GM136624)
National Institute of Allergy and Infectious Diseases (75N93019C00051, AI160397)
Defense Threat Reduction Agency (HDTRA1-18-1-0036, HDTRA1-18-1-0036)
National Science Foundation (DMS1763272)
Simons Foundation (594598)
Article History
Received: 22 November 2021
Accepted: 26 April 2022
First Online: 2 June 2022
Competing interests
: JEH-D, JF, EJP, AJ, SJ, RN, AJ, PLF and DHD own shares in Nanommune Inc. Nanommune does not sell any products described in this paper, nor funded any part of the work described herein. Neither Nanommune or its shareholders are likely to benefit from the results described in this publication. The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.